LIVE
Just published.
Human review coming soon.
Human review coming soon.
Merck Gives Weak 2026 Outlook
Merck topped its profit targets this quarter. But the company gave weak forecasts for 2026.
Revenue and profit outlooks fell short of what people expected. Merck will face trouble later in 2026.
Some of its drugs will lose their patents. Other companies will then make generic drugs. This will lower Merck's sales.
Klear Note — When drug patents expire, other companies can make cheaper generic versions. This cuts the original maker's sales significantly.
Key Terms 3
- patents
- Legal rights that let a company be the only seller of a drug.
- generic drugs
- Cheaper copies of brand-name drugs made by other companies.
- quarterly profit targets
- Money goals a company sets for every three-month period.